Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV001260448 | SCV001437455 | uncertain significance | not specified | 2020-09-30 | criteria provided, single submitter | clinical testing | Variant summary: RYR2 c.10703delT (p.Val3568GlyfsX33) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay. The predominant RYR2 mutational spectrum involves missense variants in individuals with Catecholaminergic Polymorphic Ventricular Tachycardia. Therefore, the impact of loss of function variants in RYR2 on disease is not well established. The variant was absent in 224110 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.10703delT in individuals affected with Catecholaminergic Polymorphic Ventricular Tachycardia and no experimental evidence demonstrating its impact on protein function have been reported. This RYR2 variant reportedly co-occurred with another pathogenic variant [TNNT2 c.274C>T (p.Arg92Trp)] in an affected family member (a three year old male with a maternal family history of hypertrophic cardiomyopathy; internal communication). Although, this affected proband was not tested at our laboratory, our patient tested positive for the familial TNNT2 variant but was negative for this RYR2 variant. This points to an alternative molecular basis of disease in this family thereby providing supporting evidence for a benign role of this RYR2 variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. |
| Color Diagnostics, |
RCV001806094 | SCV002052723 | uncertain significance | Cardiomyopathy | 2021-03-17 | criteria provided, single submitter | clinical testing | This variant deletes 1 nucleotide in exon 75 of the RYR2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, this variant has not been reported in individuals affected with cardiovascular disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Clinical relevance of loss-of-function truncation and splice variants in the RYR2 gene is not clearly established. The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
| All of Us Research Program, |
RCV004803605 | SCV005428057 | uncertain significance | Catecholaminergic polymorphic ventricular tachycardia | 2024-09-11 | criteria provided, single submitter | clinical testing | This variant deletes 1 nucleotide in exon 75 of the RYR2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, this variant has not been reported in individuals affected with cardiovascular disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Clinical relevance of loss-of-function truncation and splice variants in the RYR2 gene is not clearly established. The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |